Sugi Predict

Sugi Predict / Compounds / SCHEMBL1285478

SCHEMBL1285478

SCHEMBL1285478

[O-][n+]1cc(Br)cc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 3/20 0.50
▸ CYP2A6 P11509 1/20 0.41
▸ MEN1 O00255 5/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ RAB9A P51151 2/20 0.33
▸ NPC1 O15118 2/20 0.32
▸ MAOB P27338 2/20 0.32
▸ ACHE P22303 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ CASP6 P55212 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ AHR P35869 1/20 0.30
▸ MAOA P21397 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7479947 0.75 ATM (0.50) ATMMEN1KMT2ARAB9ANPC1
SCHEMBL1394239 0.75 ATM (0.50) ATMMEN1KMT2ARAB9ANPC1
SCHEMBL4164409 0.75 ATM (0.50) ATMMEN1KMT2ARAB9ANPC1
SCHEMBL2796407 0.75 ATM (0.50) ATMCYP2A6MEN1KMT2ARAB9A
SCHEMBL8512795 0.75 ATM (0.50) ATMCYP2A6MEN1KMT2ARAB9A
SCHEMBL25413825 0.75 ATM (0.50) ATMCYP2A6MEN1KMT2ARAB9A
SCHEMBL13806417 0.75 ATM (0.50) ATMMEN1KMT2ARAB9ANPC1
SCHEMBL17913534 0.75 AHR (0.35) CYP2A6AHR
SCHEMBL30948828 0.75 MEN1 (0.38) CYP2A6MEN1KMT2AMAOBAHR
SCHEMBL18572343 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117384154-A Pyrroloquinolinone compound, synthesis method and application thereof 广州医科大学 2024-01-12 — — CN disclosed
CN-110256342-B Synthetic method of 2-cyano quinoline derivative 河南省科学院化学研究所有限公司 2022-06-07 — — CN disclosed
CN-110256411-B Preparation method of 2, 3-disubstituted benzo-gamma-pyrone derivative 华侨大学 2022-06-07 — — CN disclosed
US-10654807-B2 Toll-like receptor 8 agonists THE UNIVERSITY OF KANSAS (US) 2020-05-19 — — US disclosed
CN-110256411-A A kind of 2,3- disubstituted benzenes simultaneously-preparation method of gamma-pyrone derivative 华侨大学 2019-09-20 — — CN disclosed
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 — — US disclosed
CN-108794395-A A kind of preparation method of 2- quinolinones compounds 大连理工大学 2018-11-13 — — CN disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 — — US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 — — US disclosed
EP-3230273-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG Cancer Research Technology Ltd (GB) 2017-10-18 — — EP disclosed
EP-1517895-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA INC. (CA) 2005-03-30 — — EP disclosed
EP-1436290-A1 ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR Merck Frosst Canada & Co. (CA) 2004-07-14 — — EP disclosed
WO-2004047836-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION MERCK FROSST CANADA & CO. (CA) 2004-06-10 — — WO disclosed
WO-2004045508-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO., INC. (US) 2004-06-03 — — WO disclosed
US-6743802-B2 ASTHMA THERAPY; ANTIINFLAMMATORY AGENTS MERCK FROSST CANADA & CO. (CA) 2004-06-01 — — US disclosed
WO-2004000814-A1 8-(BIARYL) QUINOLINE PDE4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-12-31 — — WO disclosed
US-20030114478-A1 Alkyne-aryl phosphodiesterase-4 inhibitors MERCK CANADA INC. (CA) 2003-06-19 — — US disclosed
WO-2003018579-A1 ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-03-06 — — WO disclosed
US-5914401-A Methods for the manufacture of quinolone carboxylic acids derivatives and intermediates thereof APOTEX, INC. (CA) 1999-06-22 — — US disclosed
US-5372813-A Measurement of serotonin uptake sites in a sample using a radio labeled substituted 6-nitroquipazine as a radioligand THE REGENTS, UNIVERSITY OF CALIFORNIA (US) 1994-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654807-B2 Toll-like receptor 8 agonists TLR8, TLR7, TLR1 ATM 1379/4885CYP2A6 3946/4885MEN1 4436/4885
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG PARG, PARP15, PARP12 ATM 2780/4885CYP2A6 576/4885MEN1 1618/4885
US-20030114478-A1 Alkyne-aryl phosphodiesterase-4 inhibitors PDE4A, PDE3B, PDE4B ATM 2517/4885CYP2A6 302/4885MEN1 4617/4885
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG PARG, PARP15, PARP12 ATM 2780/4885CYP2A6 576/4885MEN1 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.